Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders
Experimental Neurology Unit and Milan Center for Neuroscience, School of Medicine and Surgery, University Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(9), 2783; https://doi.org/10.3390/ijms19092783
Received: 8 August 2018 / Revised: 5 September 2018 / Accepted: 14 September 2018 / Published: 16 September 2018
(This article belongs to the Special Issue Cell and Molecular Biology of Pancreatic Disorders)
Diabetes is a worldwide disease which actually includes different disorders related to glucose metabolism. According to different epidemiological studies, patients affected by diabetes present a higher risk to develop both acute and chronic pancreatitis, clinical situations which, in turn, increase the risk to develop pancreatic cancer. Current therapies are able to adjust insulin levels according to blood glucose peak, but they only partly reach the goal to abrogate the consequent inflammatory milieu responsible for diabetes-related diseases. In recent years, many studies have investigated the possible use of adult mesenchymal stem cells (MSCs) as alternative therapeutic treatment for diabetes, with promising results due to the manifold properties of these cells. In this review we will critically analyze the many different uses of MSCs for both diabetes treatment and for the reduction of diabetes-related disease development, focusing on their putative molecular mechanisms.